Health care is the most dynamic industry in the Australian market, and in the industry, there is always a need to develop new treatments to improve patients’ health conditions because of the increasing chronic diseases across the world. Development of innovative solutions and digitalisation in the pharmaceutical industry have made it one of the rapidly progressing industries. With the evolution of the digital health care services in the health care industry, the detection or diagnosis of diseases and identification of accurate treatment has become easy now a days.
Let’s discuss what’s recent with five health care stocks, listed on ASX.
Total Brain Limited (ASX: TTB)
ASX listed health care company, Total Brain Limited (ASX: TTB) was founded in 2000 by leading neuroscientist Dr. Evian Gordon with the mission of improving mental fitness and health by using self-awareness and training programs. The company’s Software as a Service (SaaS) platform helps individuals scientifically optimise and measure their brain capacities while managing the risk of common mental conditions.
Recently, TTB announced that Morgan Stanley and its subsidiaries listed in Annexure A ceased to be a substantial holder in the company, effective 14 November 2019.
On 18 November 2019, Total Brain announced a change in the management team, as Joint Company Secretary Mr Harvey Bui stepped down. Meanwhile, the company unveiled the appointment of Mr Nathan Jong as the new Joint Company Secretary, effective 18 November 2019. Mr Jong is a qualified CA with more than ten years of experience in providing finance and corporate compliance advisory services to various businesses including multinational ASX/NASDAQ listed companies.
The company’s stock was trading at $0.100, down by 13.043% on 19 November 2019 (AEST 01:00 PM) with approximately 952.88 million outstanding shares and a market capitalisation of nearly $109.58 million. The stock, which has a 52 weeks high price of $0.120 and a 52 weeks low price of $0.019, has delivered a return of 249.81% on a YTD basis and 310.71% in the last six months.
AFT Pharmaceuticals Limited (ASX: AFP)
AFP is engaged in developing, licencing and selling pharmaceutical products in Australasia and globally, with a total of four offices and five R&D networks. The company has product licences in over 120 countries, and more than 130 products are available in the Australasia region.
Licencing Agreements for Maxigesic (Pain Relief Medication)
According to a recent ASX update, AFT Pharma has signed licencing agreements for its product Maxigesic® (pain relief medication) in Vietnam, Germany and Pakistan. The three countries have pain relief markets worth more than US$1 billion.
In Germany, the company signed the deal with the German affiliate of Austria’s EVER Valinject GmbH. In the European nation, the company has already secured regulatory approval for Maxigesic tablets, and this agreement was the last obstacle to making first sales in an analgesic market valued at US$564 million.
The company is expecting the first sale of Maxigesic in Germany in the calendar year 2020. Sales in Vietnam and Pakistan market are expected in 2022, dependent on the regulatory approvals. The agreement in Pakistan is with Excel Laboratories while in Vietnam, the company signed the deal with Ben Tre Pharmaceutical Joint Stock Company.
The company’s stock last traded at $2.890 on 18 November 2019. The stock has delivered a return of 52.11% on a YTD basis, with approximately 97.31 million outstanding shares and a market capitalisation of nearly $281.22 million.
CLINUVEL PHARMACEUTICALS LTD (ASX: CUV)
Biopharmaceutical company, CUV is into developing therapies for skin disorders. SCENESSE® targeting erythropoietic protoporphyria (EPP) is the lead product of CLINUVEL, for which the company has completed phase II and phase III trials in the United States and Europe.
Key Highlights for September Quarter 2019
- Cash receipts of the company were $9,782,000 for the quarter ended 30 September 2019.
- Overall cash flows for the September quarter 2019 continue to be positive.
- Cash and cash equivalents for this quarter increased by $4,067,000 to $58,336,000.
- Net cash from operating activities in the September quarter increased by $5,385,000.
The company’s stock was trading at $29.940, down by 3.138% on 19 November 2019 (AEST 01:16 PM). The stock, which has a 52 weeks high price of $45.880 and a 52 weeks low price of $15.750, has delivered a return of 71.72% on a year to date basis. The company has approximately 49.41 million outstanding shares and a market capitalisation of nearly $1.53 billion.
Nanosonics Limited (ASX: NAN)
Based in New South Wales, health care company Nanosonics Limited (ASX: NAN) is engaged in the development and commercialisation of infection control solutions. The company’s unique and first product- automated trophon® device is a ubiquitous solution for reducing cross-contamination between patients and is a proprietary automated technology for low temperature, high-level disinfection (HLD) of ultrasound probes.
2019 AGM Presentation
Recently, the company updated the market with AGM presentation for 2019, in which CEO and President of the company, Michael Kavanagh gave a brief about the company and its performance during the year ended 30 June 2019.
- Growth in revenue during the reported year is supporting strong financial position for ongoing investment.
- The company generated total revenue of $84.3 million in FY2019, up by 39% year on year.
- Profit before tax for FY2019 was $16.8 million, up 201% on prior corresponding period.
- At the end of FY2019, cash and cash equivalents stood at $72.2 million, representing an increase of $2.8 million from the same period a year ago.
- Free cash flow for FY2019 was reported at $2.6 million compared with $6.2 million in the prior period.
- Nanosonics established its Japanese entity (Nanosonics Japan K.K.) during FY2019.
- Its trophon2 regulatory approval secured in the fiscal year 2019.
- Agreements executed with various distribution partners, including GE Healthcare Japan. Moreover, some distribution agreements are currently under discussion.
Source: Company’s Report
Significant investments are being made in R&D with investment going up by 32% to $15 million in the fiscal year 2020.
The company’s stock was trading at $7.220, down by 0.138% on 19 November 2019 (AEST 01:24 PM). The stock, which has a 52 weeks high price of $7.600 and a 52 weeks low price of $2.650, has delivered a return of 160.07% on a year to date basis. The company has approximately 300.36 million outstanding shares and a market capitalisation of nearly $2.17 billion.
Cochlear Limited (ASX: COH)
A global leading medical device company Cochlear Limited (ASX: COH) is engaged in manufacturing and supply of implantable hearing solutions, that deliver a lifetime of hearing outcomes. The company sells its products in over 100 countries and operates through the segments spanning across Americas, EMEA and the Asia Pacific regions.
FDA Approval for Cochlear™ Osia® 2 System
On 18 November 2019, Cochlear announced to have secured FDA approval for the Cochlear™ Osia® 2 System.
The system is the world’s first active osseointegrated steady-state implant, which is indicated and approved in the Unites States for adults and children (?12 years) with conductive hearing loss, mixed hearing loss and single-sided sensorineural deafness. Cochlear would start the commercialisation of the system in the United States during the second half of the fiscal year 2020.
The company’s stock was trading at $225.920, up by 0.898% on 19 November 2019 (AEST 01:27 PM). The stock, which has a 52 weeks high price of $226.710 and a 52 weeks low price of $155.220, has delivered a return of 28.02% on a year to date basis. The company has approximately 57.83 million outstanding shares and a market cap of nearly $12.95 billion.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.